Affiliate Disclosure
This article contains affiliate links. If you purchase through these links, we may earn a commission at no additional cost to you. This does not influence our evaluations or rankings.
The Dr. Hugo hyperbaric chamber is a hard-shell, sit-in cabin made by LANNX Bio&Med Co. that reaches 1.5 ATA and sells for roughly $6,000 to $10,000 for the entry Sitting Pod. It is one of the most popular mild HBOT chambers for clinics, wellness centers, and home users who want higher pressure than the 1.3 ATA soft-shell ceiling without a clinical-grade price. It carries CE and ISO 13485 certification, not FDA clearance, which is the key limitation for US buyers.
What Makes the Dr. Hugo Sitting Pod Different?
The defining feature of Dr. Hugo’s most popular model is its upright seated design. Most portable chambers require you to lie down in a cylinder measuring 6 to 8 feet long. The Sitting Pod lets you sit in a compact cabin roughly the size of a phone booth, which changes the floor-space math for a home or clinic room.
- Floor footprint: about 4 by 4 feet vs 4 by 8 feet for lying chambers
- Ceiling clearance: standard 8-foot ceilings are sufficient
- During-session activities: users can read, use a laptop on external power, or meditate
- Entry style: a walk-in door rather than a horizontal zipper, easier for older users or those with mobility limits
Dr. Hugo Sitting Pod Specifications
| Specification | Detail |
|---|---|
| Footprint | Approx. 4 by 4 ft (upright cabin) |
| Entry style | Walk-in door |
| Max pressure | 1.5 ATA |
| Oxygen delivery | Concentrator O2 via mask |
| Construction | Hard-shell cabin |
| Certification | CE, ISO 13485 (not FDA-cleared) |
| Warranty | Manufacturer warranty, terms vary by dealer |
| Price | $6,000 to $10,000 (Sitting Pod) |
Does 1.5 ATA Matter More Than 1.3 ATA?
Dr. Hugo’s selling point over FDA-cleared US brands is pressure. The Sitting Pod and UDR-series models reach 1.5 ATA versus the 1.3 ATA maximum for all OxyHealth, Summit to Sea, and Newtowne soft-shell chambers. The 0.2 ATA difference is not trivial, but its clinical relevance is specific rather than general.
- Mild TBI evidence sits at 1.5 ATA: a systematic review by Harch (2022) in Frontiers in Neurology found the strongest clinical evidence for mild HBOT in persistent post-concussion syndrome at 1.5 ATA with oxygen, not 1.3 ATA. Four randomized trials met Centre for Evidence-Based Medicine Level 1 criteria at that pressure and dose (40 sessions).3
- Tissue oxygenation scales with pressure: a study by Sack et al. (2024) measured transcutaneous oxygen in chronic ulcer patients at roughly 161 mmHg at 1.4 ATA versus 333 mmHg at 2 ATA, about half the oxygen delivery at the lower pressure.4
- 1.5 ATA is still below the clinical threshold: Burman (2019) in the South African Medical Journal notes that chambers at 1.4 ATA or below are recognized only for acute mountain sickness, and that therapeutic HBOT for UHMS-approved conditions requires a minimum of 2 ATA with near-100% oxygen.5 The Dr. Hugo sits in a middle tier: above the soft-shell ceiling, below clinical pressure.
The honest reading is that 1.5 ATA buys you the pressure at which the best post-concussion evidence exists, but it does not turn a wellness chamber into a device for UHMS-approved indications like diabetic wounds or radiation injury, which still need 2.0 to 3.0 ATA.6
Is the Dr. Hugo Chamber FDA Approved?
No. The Dr. Hugo holds CE certification and ISO 13485 quality-management certification, and neither is equivalent to FDA clearance. This is the most important section for US buyers.2 CE certification means the device meets European safety standards; ISO 13485 means the manufacturing quality system meets an international standard.
The three differences that matter in the US:
- Legal sale as a medical device: requires FDA 510(k) clearance. CE does not satisfy this requirement.
- Liability: in a US product-liability claim, the absence of FDA clearance is a significant factor.
- Insurance: some health and home policies do not cover damages from non-FDA-cleared medical devices.
If FDA clearance is non-negotiable for you, the FDA-cleared alternatives are the OxyHealth and Summit to Sea lines, both cleared but capped at 1.3 ATA.
Who Should Buy a Dr. Hugo Chamber?
Dr. Hugo makes sense for buyers who want 1.5 ATA in a hard-shell sit-in format and accept CE certification instead of FDA clearance. It is a poor fit for US buyers who need a cleared device or who expect clinical-grade treatment.
It fits:
- Clinic and wellness operators who want a commercially capable chamber below clinical-grade pricing ($6,000 to $10,000 vs $80,000-plus for Perry or Sechrist monoplace units)
- Home users outside the US where CE certification is the relevant standard
- Space-constrained buyers who cannot fit a lying chamber but want a hard-shell upright option
It does not fit:
- US buyers who require FDA clearance for regulatory, insurance, or liability reasons
- Users needing clinical-grade treatment, since 1.5 ATA is still below the 2.0 to 3.0 ATA required for UHMS-approved conditions
Before you commit, run the numbers against comparable units in the hyperbaric chamber cost guide and the best home chamber rankings.
How Does Dr. Hugo Compare to OxyHealth and Summit to Sea?
Against its closest competitors, Dr. Hugo offers the lowest entry price to 1.5 ATA in a sit-in format. The trade-off is CE certification rather than FDA clearance, which for US buyers is a real regulatory difference, not a technicality.
Dr. Hugo vs Closest Competitors
| Brand | Max Pressure | FDA Cleared | Price | Made In |
|---|---|---|---|---|
| Dr. Hugo Sitting Pod | 1.5 ATA | No (CE) | $6,000 to $10,000 | China |
| OxyHealth Vitaeris 320 | 1.3 ATA | Yes | $18,000 to $23,000 | USA |
| Summit to Sea Grand Dive | 1.3 ATA | Yes | $6,500 to $8,500 | USA |
| OxyRevo Apex32 | 1.5 ATA | No (CE) | $8,499 | International |
| Newtowne C4-27 | 1.3 ATA | Yes | $4,495 | USA |
The pattern is clear: you can pay less for FDA clearance at 1.3 ATA (Newtowne, Summit to Sea), or pay a similar price for 1.5 ATA without clearance (Dr. Hugo, OxyRevo). Which trade-off is right depends entirely on whether FDA status matters for your use, location, and liability exposure.
Sources
- LANNX Bio&Med Co. “Dr. Hugo Sitting Pod and UDR-series hyperbaric chamber specifications.” lannx.net. Accessed August 2026. (Pressure, footprint, and pricing are manufacturer and dealer figures.)
- US Food and Drug Administration. “Medical Device Overview and 510(k) Premarket Notification.” fda.gov/medical-devices. Accessed August 2026. CE certification and FDA clearance are separate regulatory frameworks; CE does not satisfy FDA 510(k) requirements.
- Harch PG. “Systematic Review and Dosage Analysis: Hyperbaric Oxygen Therapy Efficacy in Mild Traumatic Brain Injury Persistent Postconcussion Syndrome.” Frontiers in Neurology, 2022;13:815056. PMID: 35370898. DOI: 10.3389/fneur.2022.815056
- Sack RA, Pikkel YY, Leitner Shemy O, Ramon Y, Ullmann Y, Zeltzer AA. “Transcutaneous oximetry values in chronic ulcer patients during hyperbaric treatment at 1.4 ATA compared to 2 ATA.” Undersea & Hyperbaric Medicine, 2024;51(1):1-5. PMID: 38615347
- Burman F. “Low-pressure fabric hyperbaric chambers.” South African Medical Journal, 2019;109(4):238-240. PMID: 31084683
- Undersea and Hyperbaric Medical Society. Hyperbaric Oxygen Therapy Indications, 14th ed. uhms.org. Accessed August 2026.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
Why Trust Our Evaluations
Our rankings are based on hands-on testing, published clinical data, and verified manufacturer specifications. We apply the same criteria to every product regardless of affiliate status. Editorial Process · Evaluation Methodology
